1 |
Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management. Front Pharmacol 2022;13:1088031. [PMID: 36699080 DOI: 10.3389/fphar.2022.1088031] [Reference Citation Analysis]
|
2 |
Rosner MH, Darmon M, Ostermann M. Onco-nephrology: what the intensivist needs to know. Intensive Care Med 2022. [PMID: 35943571 DOI: 10.1007/s00134-022-06840-9] [Reference Citation Analysis]
|
3 |
Garcia de Herreros M, Esposito F, Sauri T, Font C. Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel. J Oncol Pharm Pract 2022;:10781552221114653. [PMID: 35876362 DOI: 10.1177/10781552221114653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Pham B, Kwon SM, Castillo DR, Majeed Y, Ahmad S, Hou J, Ganesan L, Mohammad S, Cao H. Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review. J Oncol Pharm Pract. [DOI: 10.1177/10781552221092329] [Reference Citation Analysis]
|
5 |
Filippone EJ, Newman ED, Li L, Gulati R, Farber JL. Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review. Front Immunol 2021;12:780107. [PMID: 34858436 DOI: 10.3389/fimmu.2021.780107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|